Bristol-Myers Squibb Company (NYSE:BMY) and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership. Under the agreement, Bristol-Myers Squibb will fund research efforts at Tsinghua University's School of Life Sciences to identify and validate novel targets in oncology and immunoscience.

H. Lundbeck A/S (Lundbeck) today announced positive top-line results from three recently completed phase III clinical studies of Lu AA21004, an investigational drug for the treatment of adults with major depressive disorder (MDD) using dosages from 10 to 20mg.

GlaxoSmithKline plc (LSE: GSK) today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences (NASDAQ: HGSI) for US$13.00 per share in cash.

The Cancer Support Community (CSC) and the Amgen Foundation, today announced the launch of Open to Options", a program designed to bridge the communications gap between physicians and patients and inspire patient confidence in making treatment decisions.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) formulation of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) 162mg weekly compared to 8 mg/kg RoACTEMRA intravenous (IV) formulation every 4 weeks.

Abbott (NYSE: ABT) and Action Pharma A/S, a privately owned company, announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma. AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in patients at increased risk and has further potential in adjacent indications.

Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals. Under the terms of the agreement, Novartis will acquire the business, which is based in Melville, New York, for USD 1.525 billion in an all-cash transaction.